4 completed, 1 terminated. 5 Phase 1.
By phase and status
Follow RO6870810: new trials by email Literature Review of RO6870810 trials Research Report on RO6870810
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Atezolizumab, RO6870810 - Advanced Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | Hoffmann-La Roche | 36 | 2017-11-08 | 2020-11-06 |
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
RO6870810, Venetoclax, Rituximab - Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma | Phase 1 | Completed | Hoffmann-La Roche | 39 | 2017-08-28 | 2022-01-24 |
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
RO6870810, daratumumab - Multiple Myeloma | Phase 1 | Completed | Hoffmann-La Roche | 24 | 2017-06-26 | 2020-02-07 |
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome
RO6870810 - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Hoffmann-La Roche | 26 | 2014-11-06 | 2017-12-11 |
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies
RO6870810 - Solid Tumors, Advanced Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 52 | 2013-10-16 | 2018-01-05 |
Conditions studied
Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Triple Negative Breast Neoplasms (1)
Sponsors
Hoffmann-La Roche (5)
Countries
United States (5) · Australia (3) · Denmark (2) · United Kingdom (2) · Canada (1) · Spain (1)
Results publications
PMID 33311588, PMID 33586590, PMID 34581757, PMID 40102759
NIH funding
2017 (2), 2016 (1)